

(2010) in bulk active pharmaceutical ingredient (API) form for distribution to the company's customers.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Cambrex Charles City, Inc. to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated Cambrex Charles City, Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance listed.

Dated: March 21, 2011.

Joseph T. Rannazzisi,
*Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.*

[FR Doc. 2011-7539 Filed 3-30-11; 8:45 am]

B I L L I N G C O D E 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances: Notice of Registration

By Notice dated November 1, 2010, and published in the **Federal Register** on November 12, 2010, 75 FR 69464, Cerilliant Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas 78665-2402, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Drug	Schedule
Cathinone (1235)	I
Methcathinone (1237)	I
N-Ethylamphetamine (1475)	I
N,N-Dimethylamphetamine (1480).	I
Aminorex (1585)	I
4-Methylaminorex (cis isomer) (1590).	I
Gamma-Hydroxybutyric acid (2010).	I
Methaqualone (2565)	I
Alpha-ethyltryptamine (7249)	I
Lysergic acid diethylamide (7315).	I

Drug	Schedule	Drug	Schedule
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (7348).	I	Acetyl-alpha-methylfentanyl (9815).	I
Marihuana (7360)	I	Beta-hydroxyfentanyl (9830)	I
Tetrahydrocannabinols (7370)	I	Beta-hydroxy-3-methylfentanyl (9831).	I
Mescaline (7381)	I	Alpha-Methylthiofentanyl (9832)	I
3,4,5-Trimethoxyamphetamine (7390).	I	3-Methylthiofentanyl (9833)	I
4-Bromo-2,5-dimethoxyamphetamine (7391).	I	Thiofentanyl (9835)	I
4-Bromo-2,5-dimethoxyphenethylamine (7392).	I	Amphetamine (1100)	II
4-Methyl-2,5-dimethoxyamphetamine (7395).	I	Methamphetamine (1105)	II
2,5-Dimethoxyamphetamine (7396).	I	Lisdexamfetamine (1205)	II
2,5-Dimethoxy-4-ethylamphetamine (7399).	I	Phenmetrazine (1631)	II
3,4-Methylenedioxyamphetamine (7400).	I	Methylphenidate (1724)	II
5-Methoxy-3,4-methylenedioxyamphetamine (7401).	I	Amobarbital (2125)	II
N-Hydroxy-3,4-methylenedioxyamphetamine (7402).	I	Pentobarbital (2270)	II
3,4-Methylenedioxy-N-ethylamphetamine (7404).	I	Secobarbital (2315)	II
3,4-Methylenedioxymethamphetamine (7405).	I	Glutethimide (2550)	II
4-Methoxyamphetamine (7411) ..	I	Nabilone (7379)	II
Alpha-methyltryptamine (7432) ..	I	1-Phenylcyclohexylamine (7460)	II
Bufotenine (7433)	I	Phencyclidine (7471)	II
Diethyltryptamine (7434)	I	1-Piperidinocyclohexanecarbonitrile (8603).	II
Dimethyltryptamine (7435)	I	Alphaprodine (9010)	II
Psilocybin (7437)	I	Cocaine (9041)	II
Psilocyn (7438)	I	Codeine (9050)	II
5-Methoxy-N,N-diisopropyltryptamine (7439).	I	Dihydrocodeine (9120)	II
N-Benzylpiperazine (7493)	I	Oxycodone (9143)	II
Acetyldihydrocodeine (9051)	I	Hydromorphone (9150)	II
Benzylmorphine (9052)	I	Diphenoxylate (9170)	II
Codeine-N-oxide (9053)	I	Benzoylcegonine (9180)	II
Dihydromorphone (9145)	I	Ethylmorphine (9190)	II
Heroin (9200)	I	Hydrocodone (9193)	II
Hydromorphinol (9301)	I	Levomethorphan (9210)	II
Methyldihydromorphone (9304) ...	I	Lorphanol (9220)	II
Morphine-N-oxide (9307)	I	Isomethadone (9226)	II
Normorphine (9313)	I	Meperidine (9230)	II
Pholcodine (9314)	I	Meperidine intermediate-A (9232).	II
Acetylmethadol (9601)	I	Meperidine intermediate-B (9233).	II
Allylprodine (9602)	I	Meperidine intermediate-C (9234).	II
Alphacetylmethadol except levo-alphacetylmethadol (9603).	I	Methadone (9250)	II
Alphameprodine (9604)	I	Methadone intermediate (9254)	II
Alphamethadol (9605)	I	Dextropropoxyphene, bulk (non-dosage forms) (9273).	II
Betacetylmethadol (9607)	I	Morphine (9300)	II
Betameprodine (9608)	I	Thebaine (9333)	II
Betamethadol (9609)	I	Levo-alphacetylmethadol (9648)	II
Betaprodine (9611)	I	Oxymorphone (9652)	II
Hydroxypethidine (9627)	I	Noroxymorphone (9668)	II
Noracymethadol (9633)	I	Racemethorphan (9732)	II
Norlevorphanol (9634)	I	Alfentanil (9737)	II
Normethadone (9635)	I	Sufentanil (9740)	II
Trimeperidine (9646)	I	Tapentadol (9780)	II
Phenomorphan (9647)	I	Fentanyl (9801)	II
1-Methyl-4-phenyl-4-propionoxypiperidine (9661).	I		
Tilidine (9750)	I		
Para-Fluorofentanyl (9812)	I		
3-Methylfentanyl (9813)	I		
Alpha-Methylfentanyl (9814)	I		

The company plans to manufacture small quantities of the listed controlled substances to make reference standards which will be distributed to their customers.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Cerilliant Corporation to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Cerilliant Corporation to

The company plans to manufacture small quantities of the listed controlled substances to make reference standards which will be distributed to their customers.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Cerilliant Corporation to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Cerilliant Corporation to

ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.

Dated: March 21, 2011.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2011-7547 Filed 3-30-11; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF LABOR

Employment and Training Administration

Notice of Funding Opportunity and Solicitation for Grant Applications (SGA) for the Young Parents Demonstration

AGENCY: Employment and Training Administration, Labor.

ACTION: Notice of Solicitation for Grant Applications (SGA).

Funding Opportunity Number: SGA/DFA PY-10-12

SUMMARY: The Employment and Training Administration (ETA), U.S. Department of Labor announces the availability of approximately \$5.5 million authorized by the Consolidated Appropriations Act of 2010 to support applicants in providing intensive mentoring services to low-income young parents (both mothers and fathers, and expectant parents ages 16 to 24) participating in workforce development programs. Activities under this SGA are authorized under Section 171(b) of the Workforce Investment Act, which allows for demonstration and pilot projects for the purpose of developing and implementing techniques and approaches, and demonstrating the effectiveness of specialized methods, in addressing employment and training needs.

The complete SGA and any subsequent SGA amendments, in connection with the Consolidated Appropriations Act of 2010 is described in further detail on ETA's Web site at <http://www.doleta.gov/grants> or on <http://www.grants.gov>. The Web sites provide application information,

eligibility requirements, review and selection procedures and other program requirements governing this solicitation.

DATES: The closing date for receipt of applications is April 29, 2011.

FOR FURTHER INFORMATION CONTACT:

Latifa Jeter, 200 Constitution Avenue, NW., Room N4716, Washington, DC 20210; Telephone: 202-693-3553.

Signed at Washington, DC, this 25th day of March, 2011.

Eric D. Luetkenhaus,

Grant Officer, Employment and Training Administration.

[FR Doc. 2011-7556 Filed 3-30-11; 8:45 am]

BILLING CODE 4510-FN-P

NATIONAL SCIENCE FOUNDATION

National Science Board; Sunshine Act Meetings; Notice

The National Science Board's Committee on Education and Human Resources (CEH), pursuant to NSF regulations (45 CFR part 614), the National Science Foundation Act, as amended (42 U.S.C. 1862n-5), and the Government in the Sunshine Act (5 U.S.C. 552b), hereby gives notice in regard to the scheduling of a teleconference for the transaction of National Science Board business and other matters specified, as follows:

DATE AND TIME: April 7, 2011, 10:30 a.m.-12 p.m. EST.

SUBJECT MATTER: Discussion of the Committee on Education and Human Resources (CEH) STEM education prospective "action items" (to be developed at the teleconference) and discussion of the May 10-11, 2011 CEH meeting agenda.

STATUS: Open.

LOCATION: This meeting will be held by teleconference at the National Science Board Office, National Science Foundation, 4201 Wilson Blvd., Arlington, VA 22230. A room will be available for the public to listen-in to this meeting held by teleconference at Stafford Place I, National Science Foundation, 4201 Wilson Blvd., Arlington, VA 22230. All visitors must contact the Board Office [call 703-292-7000 or send an e-mail message to nationalsciencebrd@nsf.gov] at least 24 hours prior to the teleconference for the room number and provide name and organizational affiliation. All visitors must report to the NSF visitor desk located in the lobby at the 9th and N. Stuart Streets entrance on the day of the teleconference to receive a visitor's badge.

UPDATES AND POINT OF CONTACT: Please refer to the National Science Board Web

site <http://www.nsf.gov/nsb> for additional information and schedule updates (time, place, subject matter or status of meeting) may be found at <http://www.nsf.gov/nsb/notices/>. Point of contact for this meeting is: Matthew B. Wilson, National Science Board Office, 4201 Wilson Blvd., Arlington, VA 22230. Telephone: (703) 292-7000.

Daniel A. Lauretano,

Counsel to the National Science Board.

[FR Doc. 2011-7694 Filed 3-29-11; 11:15 am]

BILLING CODE 7555-01-P

NUCLEAR WASTE TECHNICAL REVIEW BOARD

Board Meeting: April 27, 2011—Amherst, New York; the U.S. Nuclear Waste Technical Review Board Will Meet To Discuss the West Valley Demonstration Project

Pursuant to its authority under section 5051 of Public Law 100-203, Nuclear Waste Policy Amendments Act of 1987, the U.S. Nuclear Waste Technical Review Board will hold a public meeting in Amherst, New York, on Wednesday, April 27, 2011, to discuss the West Valley Demonstration Project (WVDP). Currently planned are presentations on the WVDP by representatives of the New York State Energy Research and Development Authority and the U.S. Department of Energy's (DOE) Office of Environmental Management. Other issues expected to be discussed include previous reprocessing and vitrification activities at the WVDP; long-term onsite storage of vitrified high-level radioactive waste (HLW); determination of waste classification of the melter from the vitrification facility; and the final Environmental Impact Statement and Record of Decision on decommissioning and/or long-term stewardship at the WVDP. Also planned are presentations and a panel discussion on the 2008-9 study on Quantitative Risk Assessment of the State Licensed Radioactive Waste Disposal Area.

The meeting will be held at the Buffalo Marriott Niagara; 1340 Millersport Highway; Amherst, New York 14221; (tel) 716-689-6900; (fax) 716-689-0483. A block of rooms has been reserved at the hotel for meeting attendees. To ensure receiving the meeting rate, room reservations must be made by April 8, 2011.

Reservations can be made online at <http://www.buffaloniagamariott.com> using the following procedure: In the "Rates & Availability" box, enter the reservation dates; click "Special Rates &